Calcitonin

Phase 3Small molecule

TTarsa Therapeutics, Inc.

Calcitonin is one of 195 small molecule programs targeting Nephrogenic Diabetes Insipidus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

194

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nephrogenic Diabetes InsipidusActive, not recruiting

AmputationActive, not recruiting

Inflammatory Bowel DiseaseActive, not recruiting

Spinal Cord InjuryActive, not recruiting

CalcitoninRecruiting

ESSCompleted

TreatmentRecruiting

Nephrogenic Diabetes InsipidusPreclinical

Active, not recruiting

AmputationPreclinical

Active, not recruiting

Inflammatory Bowel DiseasePreclinical

Active, not recruiting

Spinal Cord InjuryPreclinical

Active, not recruiting

CalcitoninPhase 3

Recruiting

ESSPreclinical

Completed

TreatmentPhase 3

Recruiting

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Calcitonin

TTarsa Therapeutics, Inc.

Phase 3

1 2

Dexilant

Takeda

Preclinical

2 3

Alfenta

Jazz Pharmaceuticals

Preclinical

1 4

Lamprene

Novartis

Preclinical

1 5

Emtriva

Gilead

Preclinical

1 6

Foscavir

CClinigen, Inc.

Preclinical

6 7

Valium

Akero Therapeutics

Preclinical

2 8

Lotemax

PPharmos

Preclinical

1 9

Norpramin

VValidus Pharmaceuticals

Preclinical

1 10

Barhemsys

Tibotec Pharmaceuticals, Ireland

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Treatment

NCT03935984

Q2 2027

N/ARecruiting

Spinal Cord Injury

NCT05805683

Q4 2027

Phase 3Recruiting

Calcitonin

NCT07655804

Clinical

Trials by Indication[1]

Hypothyroidism1 trial

Hypothyroidism Treated With Calcitonin

Completed·UUniversity of Maryland, Baltimore·Phase 4·NCT03342001·11 enrolled

Calcinosis1 trial

Phase II Study of Calcitonin for Tumoral Calcinosis

Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00004358·9 enrolled

Amputation1 trial

Epidural Calcitonin in Lower Limb Amputation

Completed·TTanta University·N/A·NCT02115360·60 enrolled

Women1 trial

A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women

Completed·TTarsa Therapeutics, Inc.·Phase 3·NCT00959764·565 enrolled

Granuloma1 trial

Efficacy of Nasal Spray Calcitonin on Recurrence of Aggressive Central Giant Cell Granuloma

Completed·SShiraz University of Medical Sciences·Phase 2·NCT02358304·24 enrolled

6 more indications

Inflammatory Bowel Disease1 trial

Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease

Completed·—·N/A·NCT00114803·66 enrolled

ESS1 trial

FGF-23 Suppressibility by Calcitonin

Completed·RRijnstate Hospital·N/A·NCT00688077·49 enrolled

Spinal Cord Injury1 trial

Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury

Recruiting·TTanta University·N/A·NCT05805683·50 enrolled

Treatment1 trial

Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity

Recruiting·JJoseph Sferra·Phase 4·NCT03935984·37 enrolled

Nephrogenic Diabetes Insipidus1 trial

Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus

Completed·UUniversity of Colorado, Denver·N/A·NCT00478335·4 enrolled

Calcitonin1 trial

The Prophylactic Value of Subcutaneous Calcitonin in Acute Herpes Zoster Patients: A Randomized Controlled Trial

Recruiting·TTanta University·Phase 3·NCT07655804·168 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Calcitonin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Calcitonin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Calcitonin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tarsa Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTarsa Therapeutics, Inc.

Calcitonin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Trials by Indication[1]

Hypothyroidism1 trial

Calcinosis1 trial

Amputation1 trial

Women1 trial

Granuloma1 trial

Inflammatory Bowel Disease1 trial

ESS1 trial

Spinal Cord Injury1 trial

Treatment1 trial

Nephrogenic Diabetes Insipidus1 trial

Calcitonin1 trial

References

Drug Info

Quick Facts

Related News